Viromed Medical AG: UMECO Group Acquires Exclusive Marketing Rights in Asia for Cold Plasma Medical Devices ViroCAP(R) and PulmoPlas(R)

PINNEBERG, DE / ACCESS Newswire / April 1, 2025 / Viromed Medical AG ("Viromed", ticker:VMED; ISIN:DE000A3MQR65), a medical technology company and pioneer of cold plasma technology for applications in air disinfection, wound healing and intensive care medicine, has today signed an exclusive distribution agreement worth a total of EUR 152.5 million with UMECO Group ("Umeco") a leading Asian distributor of medical devices in cosmetics and medicine based in Korea, for the commercialization of the novel cold plasma medical devices ViroCAP and PulmoPlas in ten Asian countries.

Umeco acquires the exclusive marketing and distribution rights for ViroCAP and PulmoPlas in the treatment of dermatological and pneumological infections for both medical and cosmetic use. The rights cover Korea, Taiwan, Thailand, Indonesia, Japan, Shanghai, the Philippines, Singapore, Malaysia and Vietnam. Viromed will receive a one-time license fee of USD 5 million upon conclusion of the agreement as well as purchase commitments of EUR 32.5 million in 2026 and EUR 60 million in each of the years 2027 and 2028. The agreement was concluded for a term of five years.

"By partnering with a leading distribution company for medical technology, we are opening up the Asian market for our innovative cold plasma products for use in cosmetics, wound healing and intensive care medicine," explains Uwe Perbandt, CEO of Viromed Medical AG. "Thanks to its many years of experience and excellent sales network, the UMECO Group is our ideal partner for implementing Viromed's international sales strategy in Asia."

"ViroCAP and PulmoPlas perfectly complement our broad portfolio of highly innovative products in medical technology and aesthetics," adds Mark Kim, Chairman & President of UMECO Group. "We are very pleased to provide Asian patients and cosmetic users with access to Viromed's revolutionary cold plasma products, which have been shown in previous studies to be both highly effective and easy and painless to use.

About ViroCAP

ViroCAP is a portable medical device for the treatment of skin diseases using cold atmospheric plasma (KAP). ViroCAP is expected to be certified as a medical device in 2025. ViroCAP inactivates viruses, bacteria, multi-resistant pathogens and fungi and therefore the cause of many skin diseases. At the same time, the cold plasma stimulates cell biological mechanisms, thereby activating cell division, blood circulation and cell metabolism.